Published in Clin Cancer Res on March 15, 2008
New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 3.35
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res (2009) 2.62
Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60
Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol Aging (2008) 1.60
Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One (2009) 1.49
Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci U S A (2009) 1.46
The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol Cell Biol (2009) 1.42
DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res (2009) 1.33
Epigenetics and colorectal cancer pathogenesis. Cancers (Basel) (2013) 1.33
Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer (2013) 1.26
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer (2008) 1.26
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26
Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2. J Biomed Biotechnol (2010) 1.26
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res (2009) 1.23
The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget (2010) 1.20
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia (2008) 1.19
Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle (2011) 1.17
Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma. Br J Cancer (2013) 1.12
Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis (2011) 1.12
Cancer epigenetics: a brief review. ILAR J (2012) 1.09
The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene (2013) 1.05
Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One (2010) 1.05
High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer (2009) 1.04
Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans. EMBO J (2010) 1.03
A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res (2009) 1.02
Chemopreventive agent 3,3'-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res (2010) 1.00
Epigenetics Offer New Horizons for Colorectal Cancer Prevention. Curr Colorectal Cancer Rep (2012) 0.97
Epigenomic regulation of oncogenesis by chromatin remodeling. Oncogene (2016) 0.97
Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch (2011) 0.97
HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS One (2012) 0.91
Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo. Epigenetics (2012) 0.91
Epigenetic Targeting of Transforming Growth Factor β Receptor II and Implications for Cancer Therapy. Mol Cell Pharmacol (2009) 0.90
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics (2014) 0.89
The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma. Dig Dis Sci (2013) 0.88
Diverse roles of SIRT1 in cancer biology and lipid metabolism. Int J Mol Sci (2015) 0.88
The sirtuins promote Dishevelled-1 scaffolding of TIAM1, Rac activation and cell migration. Oncogene (2013) 0.88
HDAC3 as a molecular chaperone for shuttling phosphorylated TR2 to PML: a novel deacetylase activity-independent function of HDAC3. PLoS One (2009) 0.87
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget (2014) 0.87
HDAC1 and HDAC2 are differentially expressed in endometriosis. Reprod Sci (2012) 0.85
HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population. Oncol Rep (2015) 0.85
The DAC system and associations with multiple myeloma. Invest New Drugs (2010) 0.85
Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells. PLoS One (2015) 0.84
Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor. Oncotarget (2015) 0.84
HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers. Cell Mol Life Sci (2011) 0.84
Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin Pathol (2014) 0.84
Vitamin D resistance and colon cancer prevention. Carcinogenesis (2011) 0.83
HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status. Oncotarget (2015) 0.83
Potential prognostic, diagnostic and therapeutic markers for human gastric cancer. World J Gastroenterol (2014) 0.82
Black raspberries protectively regulate methylation of Wnt pathway genes in precancerous colon tissue. Cancer Prev Res (Phila) (2013) 0.82
Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry. ACS Med Chem Lett (2012) 0.81
Epigenetic biomarkers: potential applications in gastrointestinal cancers. ISRN Gastroenterol (2014) 0.81
A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma. J Cell Biochem (2012) 0.81
HDAC3 acts as a negative regulator of angiogenesis. BMB Rep (2014) 0.81
USP4 inhibits p53 and NF-κB through deubiquitinating and stabilizing HDAC2. Oncogene (2015) 0.81
Histone deacetylase 2 in the mouse hippocampus: attenuation of age-related increase by caloric restriction. Curr Alzheimer Res (2013) 0.80
Transcriptional repression of histone deacetylase 3 by the histone demethylase KDM2A is coupled to tumorigenicity of lung cancer cells. J Biol Chem (2014) 0.80
Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors. Cancers (Basel) (2010) 0.79
HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review). Oncol Lett (2014) 0.79
The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells. BMC Cancer (2015) 0.79
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clin Pharmacol (2016) 0.78
Novel (64)Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases. ACS Med Chem Lett (2013) 0.78
Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators. FASEB J (2014) 0.78
Inhibition of store-operated Ca(2+) entry counteracts the apoptosis of nasopharyngeal carcinoma cells induced by sodium butyrate. Oncol Lett (2016) 0.78
Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study. BMC Cancer (2011) 0.77
Dissecting HDAC3-mediated tumor progression. Cancer Biol Ther (2008) 0.77
Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade. Sci Rep (2016) 0.77
Plant polyphenols and oxidative metabolites of the herbal alkenylbenzene methyleugenol suppress histone deacetylase activity in human colon carcinoma cells. J Nutr Metab (2013) 0.77
Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6. Cell Death Discov (2016) 0.77
Regulation of VDR Expression in Apc-Mutant Mice, Human Colon Cancers and Adenomas. Cancer Prev Res (Phila) (2015) 0.77
Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitro. Exp Ther Med (2011) 0.76
Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer. Biomaterials (2015) 0.76
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. Antioxid Redox Signal (2015) 0.76
Making sense of HDAC2 mutations in colon cancer. Gastroenterology (2008) 0.76
Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression. Am J Cancer Res (2016) 0.75
Antitumor mechanisms of amino Acid hydroxyurea derivatives in the metastatic colon cancer model. Int J Mol Sci (2013) 0.75
A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis. Oncotarget (2017) 0.75
Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival. BMC Gastroenterol (2015) 0.75
Overexpression of caspase 7 is ERα dependent to affect proliferation and cell growth in breast cancer cells by targeting p21(Cip). Oncogenesis (2016) 0.75
The effects of a novel aliphatic-chain hydroxamate derivative WMJ-S-001 in HCT116 colorectal cancer cell death. Sci Rep (2015) 0.75
Histone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to HDAC inhibitors in vitro. Am J Cancer Res (2016) 0.75
Profiling technologies for the identification and characterization of small-molecule histone deacetylase inhibitors. Drug Discov Today Technol (2015) 0.75
HDAC Inhibitor-Induced Mitotic Arrest Is Mediated by Eg5/KIF11 Acetylation. Cell Chem Biol (2017) 0.75
Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo. Oncotarget (2015) 0.75
Lysine deacetylase (KDAC) regulatory pathways: an alternative approach to selective modulation. ChemMedChem (2014) 0.75
Estrogen-dependent downregulation of hypoxia-inducible factor (HIF)-2α in invasive breast cancer cells. Oncotarget (2016) 0.75
Global histone modification fingerprinting in human cells using epigenetic reverse phase protein array. Cell Death Discov (2017) 0.75
Microarray gene expression profiling reveals potential mechanisms of tumor suppression by the class I HDAC-selective benzoylhydrazide inhibitors. Genom Data (2015) 0.75
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis. Medicine (Baltimore) (2017) 0.75
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol (2012) 8.74
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat (2009) 7.91
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 7.21
Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med (2012) 4.24
Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2013) 3.29
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol (2008) 3.12
Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One (2012) 2.85
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch (2010) 2.72
Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res (2006) 2.68
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol (2011) 2.56
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol (2007) 2.40
Recognition of dileucine-based sorting signals from HIV-1 Nef and LIMP-II by the AP-1 gamma-sigma1 and AP-3 delta-sigma3 hemicomplexes. J Cell Biol (2003) 2.24
CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res (2003) 2.15
Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer (2008) 2.10
Rabenosyn-5 and EHD1 interact and sequentially regulate protein recycling to the plasma membrane. Mol Biol Cell (2004) 2.10
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res (2011) 2.07
Metabolite profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover. Mol Cancer (2008) 2.02
An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol (2014) 1.97
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol (2010) 1.85
CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol (2002) 1.85
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res (2004) 1.79
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res (2012) 1.77
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res (2009) 1.75
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat (2010) 1.73
Solid neuroendocrine carcinomas of the breast: metastases or primary tumors? Breast Cancer Res Treat (2010) 1.63
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One (2012) 1.61
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol (2006) 1.59
Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res (2004) 1.58
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther (2014) 1.56
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol (2010) 1.55
A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol (2009) 1.55
An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res (2010) 1.55
ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate (2003) 1.54
Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer (2006) 1.53
YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem (2003) 1.51
Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol (2005) 1.51
Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res (2005) 1.50
Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol (2008) 1.50
EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch (2010) 1.45
Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol (2011) 1.44
Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate (2004) 1.40
Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res (2006) 1.40
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn (2009) 1.38
YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res (2005) 1.37
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate (2004) 1.37
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch (2012) 1.37
Detection and segmentation of cell nuclei in virtual microscopy images: a minimum-model approach. Sci Rep (2012) 1.35
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS One (2013) 1.34
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch (2012) 1.34
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat (2011) 1.32
Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer (2011) 1.28
Specific PET imaging of xC- transporter activity using a ¹⁸F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism. Clin Cancer Res (2011) 1.27
Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer (2013) 1.26
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer (2008) 1.26
Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch (2002) 1.24
Specific regulation of the adaptor protein complex AP-3 by the Arf GAP AGAP1. Dev Cell (2003) 1.22
Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer. Neoplasia (2004) 1.20
Molecular HPV typing as a diagnostic tool to discriminate primary from metastatic squamous cell carcinoma of the lung. Am J Surg Pathol (2009) 1.19
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia (2008) 1.19